Health
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
TOKYO & BASKING RIDGE, N.J., February 03, 2026--DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/7f63150102525482b15762502a7d4e22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ECQD.CKjWGJYrIOqvkkRCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7f63150102525482b15762502a7d4e22","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population","length":175,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"If approved, DATROWAY could become the standard of care in this setting","length":71,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":246,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., February 03, 2026--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.","length":447,"tagName":"p"},{"type":"text","content":"DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.","length":197,"tagName":"p"},{"type":"text","content":"The U.S. Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Prescription Drug User Fee Act (PDUFA) date, the FDA action date for its regulatory decision, is June 2, 2026.","length":413,"tagName":"p"},{"type":"text","content":"The sBLA is based on results from the TROPION-Breast02 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress...